Phase IIa data on TMC435350 in patients with hepatitis C now presented at the ongoing AASLD

Medivir has today together with its partner Tibotec presented data from the ongoing phase IIa trial with TMC435350. These data were presented at the 59th Annual Meeting of the American Association for Study of Liver Diseases (AASLD) meeting in San Francisco held between October 31 - November 4.

TMC435350 is an investigational protease inhibitor, being developed by Tibotec in partnership with Medivir, for the treatment of hepatitis C virus (HCV). Clinical results from the ongoing phase IIa trial (OPERA-1) have now been presented in two posters and a third poster will present preclinical results.

1. Safety and antiviral activity of TMC435350 in treatment-naïve genotype 1 HCV-infected patients – M Manns et al.

2. Pharmacokinetics of TMC435350, with and without pegIFN and ribavirin, in HCV-infected individuals – G van’t Klooster et al.

3. Inhibitory activity of TMC435350 on HCV NS3/4A proteases from genotype 1 to 6 – T Lin et al.

These posters are now available on our website;

www.medivir.se under:
IR & Media / Latest events

Tibotec has also published a press release with a summery of the data presented at this congress.
This press release is to be found on our website under IR & Media / Latest events.


About hepatitis C
Chronic infection with the hepatitis C virus (HCV) leads to liver diseases. According to the WHO, 3% of the global population is infected with HCV, which means 200 million individuals. In the USA, 1.8% of the population is infected, that is 3.9 million people. In more than 60% of these cases, the HCV infection leads to chronic liver disease, cirrhosis and liver tumors. It is the most common reason for liver transplant. The HCV market is currently dominated by interferon-based treatments.

For additional information, please contact
Rein Piir, CFO & Vice President, Investor Relations, +46 708 53 72 92.